We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04445610
Recruitment Status : Unknown
Verified June 2020 by Amira Al Balakosy, Ain Shams University.
Recruitment status was:  Not yet recruiting
First Posted : June 24, 2020
Last Update Posted : June 26, 2020
Information provided by (Responsible Party):
Amira Al Balakosy, Ain Shams University

Brief Summary:
The following two mechanisms that explain the ability of measles vaccine to cause partial protection against COVID-19. The first is that measles vaccine may increase the ability of the immune system to fight off pathogens other than measles due to the generated bystander immunity that would enhance the overall immunity against the new coronavirus. The second is that SARS-CoV-2 is proven to have structure similarities with measles, which may cause cross-reactivity and immunity between measles vaccines and COVID-19, leading to partial protection against COVID-19 in vaccinated subjects

Condition or disease
Coronavirus (COVID-19)

Detailed Description:


  1. To identify Measles IgG titre in SARS-COV2 infected patients .
  2. correlate level of Measles IgG titre with the clinical severity of COVID-19 disease.

Secondary Objective To find an association of the postulated protective role of measles vaccine and SARS-COV2 infection


Inclusion criteria:included patients would be divided into 3 groups according to clinical severity of COVID-19 disease (mild ,moderate & severe)

  • All patients with confirmed COVID 19 confirmed by positive PCR . .
  • Any age or gender.

Exclusion criteria:

- Any patient refusing to be involved in the study.


  • Informed consent will be taken from each subject
  • Full clinical examination.
  • Evaluation of Measles Antibody Titer:

The measles virus IgG antibody titer will be determined quantitatively by ELISA for quantitative determination of IgG class antibodies against Measles virus in human serum or plasma (citrate, heparin).

- Anonymous data will be retrieved from the admitted patients' files, such as:

  • CBC, CRP, AST, ALT, ESR, Serum ferritin & SARS CoV 2 RNA PCR swab results.
  • Chest X ray and/or CT chest.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?
Estimated Study Start Date : July 1, 2020
Estimated Primary Completion Date : September 1, 2020
Estimated Study Completion Date : November 1, 2020

Resource links provided by the National Library of Medicine


Primary Outcome Measures :
  1. Viral clearance [ Time Frame: 6 months ]
    Achievement of two consecutive negative PCR results for COVID 19 and discharge from hospital

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
all patients with confirmed COVID-19 presented to Ain Shams Hospital

Inclusion Criteria:

  • All patients with confirmed COVID 19.
  • Any age or gender

Exclusion Criteria:

  • - Any patient refusing to be involved in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04445610

Layout table for location contacts
Contact: Amira Al Balakosy, MD 01221977455 drbalakosy@gmail.com

Layout table for location information
Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center
Cairo, Non-US, Egypt, 11566
Sponsors and Collaborators
Ain Shams University
Layout table for investigator information
Principal Investigator: Amira Al Balakosy, M.D Ain Shams University
Layout table for additonal information
Responsible Party: Amira Al Balakosy, Tropical Medicine Department. Ain Shams University, Ain Shams University
ClinicalTrials.gov Identifier: NCT04445610    
Other Study ID Numbers: FMASU P31a/ 2020
First Posted: June 24, 2020    Key Record Dates
Last Update Posted: June 26, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases